Celularity Inc
For the period ended Jun 30, 2026. Filed Oct 20, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Oct 20, 2026
CELU$0.76-0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit Number | Description |
| 4.1 | Form of Helena Note dated April 16, 2026 (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed with the Commission on April 21, 2026). |
| 4.2* | Form of Senior Secured Convertible Promissory Note (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K, filed with the Commission on September 28, 2026) |
| 4.3* | Form of Class A Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the current report on Form 8-K, filed with the Commission on September 28, 2026) |
| 4.4* | Amended and Restated Senior Secured Convertible Promissory Note, dated September 23, 2026, issued to the Philip & Daniele Barach Family Trust (incorporated by reference to Exhibit 4.3 to the current report on Form 8-K, filed with the Commission on September 28, 2026) |
| 4.5* | Amended and Restated Senior Warrant, effective as of September 23, 2026, issued to the Philip & Daniele Barach Family Trust (incorporated by reference to Exhibit 4.4 to the current report on Form 8-K, filed with the Commission on September 28, 2026) |
| 10.1 | Settlement Agreement dated May 21, 2026 by and between Celularity Inc. and Helena Global Investment Opportunities 1 Ltd. (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the Commission on May 28, 2026). |
| 10.2 | Loan Agreement dated June 29, 2026 by and between Celularity, Inc. and the Philip & Daniele Barach Family Trust (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the Commission on June 30, 2026). |
| 10.3* | Securities Purchase Agreement, dated as of September 23, 2026, by and among Celularity Inc. and the purchasers party hereto (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the Commission on September 28, 2026) |
| 10.4* | Security Agreement, dated as of September 23, 2026, by and among Celularity Inc., the other grantors party thereto and Philip Barach, as collateral agent(incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed with the Commission on September 28, 2026) |
| 10.5* | Registration Rights Agreement, dated as of September 23, 2026, by and among Celularity Inc. and the purchasers party thereto (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K, filed with the Commission on September 28, 2026) |
| 10.6* | Board Rights Agreement dated as of September 23, 2026, by and between Celularity Inc. and Philip & Daniele Barach Family Trust (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K, filed with the Commission on September 28, 2026) |
| 10.7* | Intercreditor Agreement dated as of September 23, 2026 by and among the parties thereto (incorporated by reference to Exhibit 10.5 to the current report on Form 8-K, filed with the Commission on September 28, 2026) |
| 10.8* | Settlement, Release and Termination Agreement, dated September 18, 2026 by and between Celularity Inc. and Helena Global Investment Opportunities 1 Ltd. (incorporated by reference to Exhibit 10.6 to the current report on Form 8-K, filed with the Commission on September 28, 2026) |
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS | Inline XBRL Instance Document- the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | The cover page for the Company’s quarterly report on Form 10-Q has been formatted in Inline XBRL and contained in Exhibit 101 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.